Bronchiectasis is a chronic lung disorder marked by permanent widening of the airways, recurrent respiratory infections, and impaired clearance of mucus, which can lead to persistent cough, fatigue, and progressive lung damage over time. Bronchiectasis treatment focuses on a comprehensive approach that combines infection control, airway clearance, symptom management, and prevention of disease progression. Antibiotic therapy is central, tailored to target specific pathogens identified through sputum testing, while intermittent or long-term regimens may be used to manage recurrent infections. Airway clearance techniques, including specialized physiotherapy exercises, breathing techniques, and mechanical devices, help remove mucus and reduce bacterial buildup. Adjunct therapies, such as inhaled medications, anti-inflammatory treatments, and mucolytics, support lung function and improve patient comfort. Preventive measures, including vaccinations, smoking cessation, and management of coexisting conditions, play a critical role in reducing exacerbations and maintaining lung health. In selected cases, surgical intervention or advanced therapies may be considered for localized disease or refractory symptoms. Coordination among pulmonologists, respiratory therapists, and primary care providers ensures that care is individualized, monitored, and adapted to changes in disease status. Bronchiectasis treatment emphasizes both immediate symptom relief and long-term strategies to preserve lung function, minimize hospitalizations, and enhance quality of life. By combining targeted therapies with patient-centered management plans, it is possible to achieve meaningful improvements in respiratory health and daily functioning for those affected by this chronic condition.
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Susceptibility to SARS-CoV-2 infection and nasal air conditioning ability
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Comparative evaluation of DECAF and BAP 65 scores in predicting outcomes of COPD exacerbations among in patients at Vicente Sotto Memorial Medical Center
Allanys Joy Q Pino, Vicente Sotto Memorial Medical Center, Philippines
Title :
Saurabh Chattopadhyay, University of Kentucky College of Medicine, United States
Title : Personalized and precision Medicine (PPM) as a unique healthcare model through biodesign driven and inspired biotech, translational applications and pulmonology related marketing to secure the human healthcare, wellness and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation